Oculis Holding AG (OCS) Operating Expenses (2022 - 2026)
Oculis Holding AG (OCS) recorded quarterly Operating Expenses of -$28.0 million in Q1 2026, down 6.4% quarter-over-quarter from -$26.3 million in Q4 2025, and down 24.32% on a YoY basis from -$37.0 million in Q1 2025.
Oculis Holding AG (OCS) Operating Expenses (2022 - 2026) Analysis & Trends
Oculis Holding AG's Operating Expenses history runs 5 years deep, the most recent figure standing at -$28.0 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 24.32% year-over-year to -$28.0 million; the TTM figure through Mar 2026 stood at -$25.8 billion (down 21.24% YoY), while the FY2025 annual figure was -$103.7 million, down 22.93% from the prior year.
- Operating Expenses was -$28.0 million for Q1 2026 at Oculis Holding AG, down from -$26.3 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of -$7.3 million in Q3 2022 to a low of -$25.7 billion in Q3 2025.
- Historically, Operating Expenses has averaged -$2.9 billion across 5 years, with a median of -$21.1 million in 2024.
- Biggest YoY gain for Operating Expenses was 63.43% in 2024; the steepest drop was 141836.6% in 2024.
- A 5-year view of Operating Expenses shows it stood at -$11.8 million in 2022, then slipped by 18.6% to -$13.9 million in 2023, then tumbled by 41.32% to -$19.7 million in 2024, then plunged by 33.61% to -$26.3 million in 2025, then retreated by 6.4% to -$28.0 million in 2026.
- The last three Operating Expenses figures came in at -$28.0 million (Q1 2026), -$26.3 million (Q4 2025), and -$25.7 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 4.33 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 32.68 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -138.30 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 15.76 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 574,669.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.85 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -67.40 Mn |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | -28.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.01 Mn |
| Dec 31, 2025 | -26.33 Mn |
| Sep 30, 2025 | -25.68 Bn |
| Jun 30, 2025 | -25.40 Mn |
| Mar 31, 2025 | -22.53 Mn |
| Dec 31, 2024 | -19.71 Mn |
| Sep 30, 2024 | -21.18 Bn |
| Jun 30, 2024 | -25.13 Mn |
| Mar 31, 2024 | -17.82 Mn |
| Dec 31, 2023 | -13.94 Mn |
| Sep 30, 2023 | -14.92 Mn |
| Jun 30, 2023 | -12.23 Mn |
| Mar 31, 2023 | -48.71 Mn |
| Dec 31, 2022 | -11.76 Mn |
| Sep 30, 2022 | -7.33 Mn |
| Jun 30, 2022 | -9.84 Mn |